Date published: 2025-12-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

Topotecan-d6 (CAS 1044904-10-0)

0.0(0)
Write a reviewAsk a question

Alternate Names:
(4S)-10-[(Dimethylamino-d6)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′,6-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Application:
Topotecan-d6 is a labeled DNA Topo I (topoisomerase I) inhibitor
CAS Number:
1044904-10-0
Molecular Weight:
427.48
Molecular Formula:
C23H17D6N3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Topotecan-d6 is a labeled Topotecan. A DNA Topo I (topoisomerase I) inhibitor, a semisynthetic analog of Camptothecin. Topotecan-d6 works by interfering with the cell cycle of cancer cells. Specifically, it binds to the topoisomerase I enzyme, which is involved in DNA replication and transcription. This binding prevents the enzyme from functioning properly, resulting in the inhibition of DNA replication and transcription, which ultimately leads to cell death. Topotecan-d6 can be used as an internal standard in analytical assays, such as mass spectrometry, to achieve more accurate quantification of topotecan in biological samples. The use of a deuterium-labeled compound allows for precise differentiation between the compound and its labeled counterpart, facilitating the detailed study of the compound′s absorption, distribution, metabolism, and excretion (ADME) profiles.


Topotecan-d6 (CAS 1044904-10-0) References

  1. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.  |  Kumar, S., et al. 2011. Clin Cancer Res. 17: 5656-67. PMID: 21788355
  2. An alternative approach for quantitative bioanalysis using diluted blood to profile oral exposure of small molecule anticancer drugs in mice.  |  Liederer, BM., et al. 2013. J Pharm Sci. 102: 750-60. PMID: 23225118
  3. Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers.  |  Shu, P., et al. 2020. J Oncol Pharm Pract. 26: 794-802. PMID: 31483750
  4. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer.  |  Kuehl, PJ., et al. 2021. Drug Deliv. 28: 767-775. PMID: 33860729
  5. Optimization of dihydrosphingomyelin/cholesterol mol ratio in topotecan-loaded liposomes to enhance drug retention and plasma half-life by understanding physicochemical and thermodynamic properties of the lipid membrane  |  N Kasagi, I Doi, J Nakabayashi, K Saito… - Journal of Molecular …, 2023 - Elsevier., 5 July 2023,. Journal of Molecular Structure. Volume 1283: 135333.

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Topotecan-d6, 1 mg

sc-220273
1 mg
$380.00